Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial

Table 1 Patients’ characteristics at baseline, n (%)

Characteristic		n = 144	PA < 4.60° (n = 63)	PA ≥ 4.60° (n = 81)	P (χ2, U)1
Age (years)	Median	62	64	62	0.336
	Range	22-82	35-82	22-78
Sex	Men	79 (54.9)	24 (38.1)	55 (67.9)	< 0.001
	Women	65 (45.1)	39 (61.9)	26 (32.1)
ECOG PS	0	133 (92.4)	56 (88.9)	77 (95.1)	0.167
	1	11 (7.6)	7 (11.1)	4 (4.9)
Sidedness	Left	123 (85.4)	57 (90.5)	66 (81.5)	0.129
	Right	21 (14.6)	6 (9.5)	15 (18.5)
Mutation status	Wild type	60 (41.7)	22 (34.9)	38 (46.9)	0.211
	RAS mutated	79 (54.9)	37 (58.7)	42 (51.9)
	BRAF mutated	4 (2.8)	3 (4.8)	1 (1.2)
	Unknown	1 (0.7)	1 (1.6)	0
Biological agent	anti-EGFR	59 (41.0)	23 (36.5)	36 (44.4)	0.324
	bevacizumab	81 (56.3)	37 (58.7)	44 (54.3)
	None	4 (2.8)	3 (4.8)	1 (1.2)
Primary tumor resection	Yes	117 (81.3)	49 (77.8)	68 (84.0)	0.346
	No	27 (18.8)	14 (22.2)	13 (16.0)
Liver metastases	Yes	102 (70.8)	43 (68.3)	59 (72.8)	0.548
	No	42 (29.2)	20 (31.7)	22 (27.2)
Peritoneal metastases	Yes	46 (31.9)	15 (23.8)	31 (38.3)	0.065
	No	98 (68.1)	48 (76.2)	50 (61.7)

¹Differences between groups were tested using the χ² test for categorical and U test for continuous variables.

ECOG: Eastern Cooperative Oncology Group; PS: Performance status; RAS: Rat sarcoma; EGFR: Epidermal growth factor receptor; PA: Phase angle.